TherapeuticsMD (TXMD) investors are keeping an eye on the pace of commercialization efforts for Imvexxy, Annovera, and Bijuva. That will prove critical for …
Cantor’s analyst Louise Chen assumes coverage on pharmaceutical company TherapeuticsMD (TXMD) with an Overweight rating and price target of $27, showing an upside …
Last Thursday, TherapeuticsMD (TXMD) announced that it has entered into discussions with the FDA regarding the proposed label for TX-001, the company’s experimental …
TherapeuticsMD (TXMD) is on its way to transitioning to a commercial-stage company. Recall, Imvexxy is approved for the treatment of moderate-to-severe vaginal pain …
TherapeuticsMD (NYSE:TXMD) CEO Robert Finizio and Co-founder Brian Bernick presented today at the 13th Annual Wells Fargo Securities Healthcare Conference in Boston. The management team provided a business …
Today, we list 3 biopharma companies that have FDA events approaching along with positive analyst sentiment. In other words, analysts expect these companies’ …
TherapeuticsMD (NASDAQ:TXMD) announced Friday that the FDA has approved its vaginal contraceptive system known as ANNOVERA. ANNOVERA is the first long-acting prescription birth control …
Oppenheimer analyst Jay Olson is out with a new research note on shares of TherapeuticsMD (NYSE:TXMD), following the news that the drug maker has entered into …
Oppenheimer analyst Jay Olson is out today with a bullish research note on shares of TherapeuticsMD (NASDAQ:TXMD), after the drug maker reported second-quarter results and …
Cantor analyst William Tanner is out pounding the table on shares of TherapeuticsMD (NASDAQ:TXMD), reiterating an Overweight rating and price target of $26, which implies an …
